Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
Provided By GlobeNewswire
Last update: Mar 26, 2025
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement:
Read more at globenewswire.com
